Stephen hiscox (6 Ergebnisse)

Autor
Mit der Detailsuche verfeinern

Optimieren Sie Ihre Suche

  • Bücher (6)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

    • Sprache: Englisch

      Verlag: Springer, 2010

      9048179017 / 9789048179015

      • Softcover

      Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 141,14

      EUR 10,94 Versand 
      Versand von Vereinigtes Königreich nach USA

      Anzahl: Mehr als 20 verfügbar

      Zustand: New. In English.

    • Sprache: Englisch

      Verlag: Springer, 2009

      1402085257 / 9781402085253

      • Hardcover

      Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 165,78

      EUR 13,18 Versand 
      Versand von Vereinigtes Königreich nach USA

      Anzahl: Mehr als 20 verfügbar

      Zustand: New. In English.

    • Sprache: Englisch

      Verlag: Springer Netherlands, 2009

      1402085257 / 9781402085253

      • Hardcover

      Anbieter: Buchpark, Trebbin, DeutschlandBuchpark

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Gebraucht - Sehr gut

      EUR 124,03

      EUR 105,00 Versand 
      Versand von Deutschland nach USA

      Anzahl: 1 verfügbar

      Zustand: Sehr gut. Zustand: Sehr gut | Sprache: Englisch | Produktart: Bücher | One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens. Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.

    • Sprache: Englisch

      Verlag: Springer Verlag, 2009

      1402085257 / 9781402085253

      • Hardcover

      Anbieter: Revaluation Books, Exeter, Vereinigtes KönigreichRevaluation Books

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 235,03

      EUR 11,68 Versand 
      Versand von Vereinigtes Königreich nach USA

      Anzahl: 2 verfügbar

      Hardcover. Zustand: Brand New. 1st edition. 198 pages. 9.50x6.25x0.25 inches. In Stock.

    • Sprache: Englisch

      Verlag: Springer, Springer, 2010

      9048179017 / 9789048179015

      • Softcover

      Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 223,07

      EUR 30,50 Versand 
      Versand von Deutschland nach USA

      Anzahl: 1 verfügbar

      Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens.Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.

    • Sprache: Englisch

      Verlag: Springer, 2009

      1402085257 / 9781402085253

      • Hardcover

      Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

      Verkäufer/-in mit 5 Sternen
      Verkäufer/-in kontaktieren

      Zustand: Neu

      EUR 230,74

      EUR 30,50 Versand 
      Versand von Deutschland nach USA

      Anzahl: 1 verfügbar

      Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - One of the main causes of failure in the treatment of breast cancer is the intrinsic presence of, or development of, drug resistance by the cancer cells. Recent studies on the mechanisms of cancer drug resistance have yielded important information highlighting both how tumour cells may escape these therapeutic constraints and that drug resistance may further impinge on tumour cell functions that may ultimately promote an adverse cell phenotype. New targets have been identified with potential therapeutic applications in resistant breast cancer leading to the subsequent evaluation of inhibitors of these targets in preclinical studies. Importantly, there is increasing evidence from such studies demonstrating the benefit of novel combination strategies as potential avenues for future drug regimens.Written by experts in the subject area, this book covers the molecular details and functional consequences of endocrine resistance in breast cancer with particular emphasis on the future applications of novel drug combinations that may be utilized to circumvent resistance and improve anti-tumour effects. This book represents a timely publication in the field of breast cancer research, providing current knowledge in the area of drug resistance and will be important reading material for clinicians and researchers alike.